PHILADELPHIA, PA — Proscia® has reported record-breaking growth in 2024, more than doubling its business and solidifying its position as a leader in enterprise pathology. The company now enters 2025 with a strengthened commitment to transforming pathology through AI and digital technologies, aiming to drive advancements in precision medicine for scientists, pathologists, and patients alike.
“2024 was a breakout year for Proscia,” said David West, CEO of Proscia. “And the momentum only continues to accelerate. There’s a new wave of demand as pathology and AI propel precision medicine forward. Our traction has proven that we can rewire pathology for this paradigm shift and help our customers remain at the forefront for their scientists, pathologists, and patients.”
Growing Impact of Concentriq
Proscia’s flagship Concentriq® platform saw significant expansion in 2024, with clinical users diagnosing 2.4 million patients. The company projects this volume will triple in 2025, driven by its partnerships with Agilent Technologies and Siemens Healthineers, which are expanding Concentriq’s reach across a global network of diagnostic laboratories. Currently, pharmaceutical companies responsible for 34 of the 50 top-selling drugs utilize the platform.
Recently, Concentriq earned recognition from KLAS Research, landing a spot on October’s Emerging Solutions Top 20 list for its role in improving patient outcomes. The platform was also ranked a leader by CB Insights in both general and oncology-specific digital pathology diagnostics.
Data-Driven AI Innovations
Proscia’s advancements in AI were key to its success in 2024. The launch of the Real-World Data (RWD) offering contributed to a 10x increase in the company’s RWD business, which now adds over 150,000 records monthly. Additionally, the release of Concentriq Embeddings and the Proscia AI Toolkit enabled life sciences teams to leverage foundation models for biomarker discovery, clinical trial optimization, and companion diagnostics development.
The company has also expanded its precision medicine AI portfolio, offering over 120 research and diagnostic applications on Concentriq. Notable updates include multi-AI workflows on Concentriq AP and FDA 510(k) clearance for Concentriq AP-Dx, reinforcing Proscia’s commitment to innovation in the digital pathology space.
Enhanced Customer Experience
Proscia’s focus on customer experience (CX) has played a critical role in its growth. A June 2024 KLAS Research report highlighted the success of Proscia’s CX practice in reducing deployment timelines by more than 30%, with 100% of customers surveyed indicating they would purchase Concentriq again.
“Proscia has succeeded in helping us achieve our main goal with Concentriq. Also, the vendor is ambitious and has a good support system that is willing to take an extra step to make things happen,” said one physician interviewed by KLAS.
With its CX group now encompassing professional services, technical support, and customer success, Proscia has prioritized streamlining upgrades, resolving issues faster, and enhancing training resources to support customers as digital pathology becomes central to their operations.
Looking Ahead
Equipped with a robust platform, cutting-edge AI tools, and a growing network of partners, Proscia aims to continue accelerating innovation in pathology in 2025 and beyond. The company’s ongoing efforts to expand its product offerings and customer reach aims to transform the future of pathology, making it more efficient, precise, and accessible for all.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.